Abstract
This meta-analysis assesses the efficacy and safety of triple therapy with either boceprevir or telaprevir compared to the standard of care (SoC), pegylated interferon plus ribavirin, in patients chronically infected with genotype 1 hepatitis C virus (HCV). We included 10 randomized controlled trials comprising 33 individual treatment arms which enrolled 5,312 subjects. Meta-analysis for sustained virologic response (SVR) provided evidence that triple therapy with either boceprevir or telaprevir increased response by 1.76 times (CI-95% 1.63-1.89) in comparison with SoC. However, heterogeneity was strong (I-2 79.7% p for heterogeneity
Original language | English |
---|---|
Pages (from-to) | 263-276 |
Number of pages | 14 |
Journal | New Microbiologica |
Volume | 37 |
Issue number | 3 |
Publication status | Published - 2014 |
Keywords
- Adverse event
- Boceprevir
- Direct-acting antiviral compounds
- Experienced patients
- Hepatitis C infection
- Iatrogenic disease
- Naïve patients
- Opportunistic infection
- Sustained virological response
- Telaprevir
ASJC Scopus subject areas
- Microbiology (medical)